- Home
- ANAB vs KIO Comparison
ANAB vs KIO Comparison
Compare ANAB & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- KIO
- Stock Information
- Founded
- ANAB 2005
- KIO 2011
- Country
- ANAB United States
- KIO United States
- Employees
- ANAB N/A
- KIO 2400
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- KIO Investment Managers
- Sector
- ANAB Health Care
- KIO Finance
- Exchange
- ANAB Nasdaq
- KIO Nasdaq
- Market Cap
- ANAB 630.2M
- KIO 522.7M
- IPO Year
- ANAB 2017
- KIO N/A
- Fundamental
- Price
- ANAB $21.90
- KIO $12.58
- Analyst Decision
- ANAB Buy
- KIO
- Analyst Count
- ANAB 10
- KIO 0
- Target Price
- ANAB $48.00
- KIO N/A
- AVG Volume (30 Days)
- ANAB 465.1K
- KIO 136.5K
- Earning Date
- ANAB 11-04-2025
- KIO 01-01-0001
- Dividend Yield
- ANAB N/A
- KIO 10.82%
- EPS Growth
- ANAB N/A
- KIO N/A
- EPS
- ANAB N/A
- KIO N/A
- Revenue
- ANAB $123,164,000.00
- KIO N/A
- Revenue This Year
- ANAB $11.22
- KIO N/A
- Revenue Next Year
- ANAB $8.35
- KIO N/A
- P/E Ratio
- ANAB N/A
- KIO N/A
- Revenue Growth
- ANAB 304.17
- KIO N/A
- 52 Week Low
- ANAB $12.21
- KIO $10.52
- 52 Week High
- ANAB $40.70
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- ANAB 52.43
- KIO 54.64
- Support Level
- ANAB $19.86
- KIO $12.38
- Resistance Level
- ANAB $22.98
- KIO $12.54
- Average True Range (ATR)
- ANAB 1.00
- KIO 0.10
- MACD
- ANAB 0.35
- KIO 0.01
- Stochastic Oscillator
- ANAB 69.14
- KIO 97.09
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.